课题基金 / 基金详情

项目摘要

项目成果

Theodore S Jardetzky的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Most allergic reactions are caused by immunoglobulin E (IgE) antibodies that are specific for allergens and that trigger potent inflammatory responses mediated by mast cells and basophils. IgE binds to the high affinity receptor (FcεRI) expressed on these allergic effector cells, making this a central interaction that is common to different allergen-specific responses. The anti-IgE antibody (omalizumab) is currently used to treat allergic asthma and chronic idiopathic urticaria, demonstrating the feasibility of inhibiting the IgE:FcεRI interaction for therapeutic benefit. We have developed multiple approaches to identifying small molecule ligands for the IgE and identified promising leads for further studies. In this proposal, we will further investigate these leads to explore the possibility of producing novel probes for IgE function and inhibition. !
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery and engineering of novel anti-IgE disruptive inhibitors
  • 批准号:
    10353982
  • 项目类别:
  • 资助金额:
    $23.61万
  • 财政年份:
    2021
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
Discovery and engineering of novel anti-IgE disruptive inhibitors
  • 批准号:
    10495213
  • 项目类别:
  • 资助金额:
    $19.68万
  • 财政年份:
    2021
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
  • 批准号:
    10468251
  • 项目类别:
  • 资助金额:
    $75.42万
  • 财政年份:
    2020
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
  • 批准号:
    10120270
  • 项目类别:
  • 资助金额:
    $76.77万
  • 财政年份:
    2020
  • 负责人:
    Theodore S Jardetzky
  • 依托单位:
海外基金